RetinalGenix Taps Dr. Taimour Langaee to Advance Precision Medicine Initiatives
APOLLO BEACH, Fla. – June 13, 2025 – RetinalGenix Technologies Inc. (OTCQB:RTGN), a company harnessing the power of advanced retinal imaging for precision medicine, has appointed Dr. Taimour Langaee, MSPH, PhD, as a scientific advisor. This move signals RetinalGenix’s commitment to integrating cutting-edge genomics and personalized medicine into its product pipeline, a strategy poised to reshape how we approach eye health and beyond.
The appointment of Dr. Langaee, a seasoned expert in pharmacogenomics and precision medicine, is strategic. He will spearhead initiatives focused on the Company’s DNA GPS Pharmacogenetics platform, a program designed to tailor treatment pathways for various retinal and systemic diseases. His work will encompass the analysis of genotyping and sequencing data, genetic and pharmacogenomics data analyses, and clinical studies linking eye diseases to genetic variations.
Dr. Langaee’s impressive resume boasts over two decades of experience in the complex interplay of genetics, drug response, and patient care. His background spans diverse fields, including the study of pharmacogenomics, epigenetics, and infectious diseases. He’s also been involved in major research endeavors like the NIH Warfarin Study. His experience will be critical to advancing RetinalGenix’s mission.
Currently a Professor at the University of South Florida’s Taneja College of Pharmacy, Dr. Langaee has a proven track record of mentoring and educating the next generation of medical professionals. His past experience includes directing the Center for Pharmacogenomics and Precision Medicine Genotyping Core Laboratory at the University of Florida, where he led numerous NIH-funded projects focused on personalized medicine. This combination of practical, real-world experience gives him an edge that could make him a valuable member of the team.
Jerry Katzman, MD, CEO of RetinalGenix Technologies, expressed excitement about the new advisor: “Dr. Langaee’s expertise will be invaluable as we expand our DNA GPS initiatives. His ability to translate genetic insights into actionable clinical strategies is perfectly aligned with our mission to provide personalized, data-driven solutions for health. We’re thrilled to welcome him on board.”
RetinalGenix’s strategy emphasizes the retina’s role as a window into overall health. Advanced retinal imaging, combined with genetic analysis and artificial intelligence, allows earlier detection of conditions like diabetes, hypertension, and cardiovascular disease. By integrating pharmacogenetics, high-resolution retinal imaging, remote monitoring, and AI-powered analysis, RetinalGenix aims to flag early warning signs, allowing for timely medical intervention and better overall health management.
With its remote monitoring capabilities, RetinalGenix seeks to provide healthcare providers with a proactive way to address patient needs. Furthermore, the company’s new DNA GPS Pharmacogenetics platform aims to personalize risk assessments and treatment plans based on an individual’s genetic profile. This could potentially lead to more effective interventions and proactive preventative strategies.
About RetinalGenix
RetinalGenix is focused on revolutionizing early disease detection and patient outcomes. By integrating genetic screening, advanced imaging, and therapeutic development, the company strives to detect initial physiological changes that may indicate future diseases. Its technology could play a key role in preventing vision loss and improving health outcomes by targeting diseases of the neurodegenerative, cardiovascular, vascular, metabolic, and diabetic systems, as well as Alzheimer’s and Parkinson’s disease. The company is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia, adding another layer to the company strategy.
Safe Harbor Statement
This press release contains forward-looking statements. These statements use words like “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” and similar expressions. These forward-looking statements are based on management’s expectations as of this date and are subject to risks and uncertainties. Actual results may differ from expectations due to factors including the Company’s ability to successfully complete research and further development and commercialization of Company imaging system or drug candidates, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s imaging system or drug candidates, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The Company is not obligated to update these statements.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/2417.html
